Profile - To The Moon

Woodbranch

Posts · 10Posts · 10
Following · 0Following · 0
Followers · 0Followers · 0

- WoodbranchWoodbranch
  ·2025-09-19
  $HKBN(01310)$ $HKBN(01310)$
  941 Comment
  1
  Share
  Report
- WoodbranchWoodbranch
  ·2025-08-13
  $Sea Ltd(SE)$ $Sea Ltd(SE)$ $Sea Ltd(SE)$
  1.01K Comment
  2
  Share
  Report
- WoodbranchWoodbranch
  ·2024-08-19
  $NoonTalk Media(SEJ.SI)$ Hitting 0 soon
  2.19K Comment
  1
  Share
  Report
- WoodbranchWoodbranch
  ·2024-07-29
  If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.
  Sorry, this post has been deleted
  2.69K Comment
  Like
  Share
  Report
- WoodbranchWoodbranch
  ·2024-07-18
  Share your opinion about this news…
  BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch
  (The author is a Reuters Breakingviews columnist. The opinions expressed are her own.) By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more t
  BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch
  2.00K Comment
  Like
  Share
  Report
- WoodbranchWoodbranch
  ·2024-02-07
  Anyone has the full article
  Sorry, this post has been deleted
  2.92K Comment
  Like
  Share
  Report
- WoodbranchWoodbranch
  ·2022-03-08
  $Grab Holdings(GRAB)$if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps
  3.21K Comment
  3
  Share
  Report
No followers yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583414482292207","uuid":"3583414482292207","gmtCreate":1620322003768,"gmtModify":1635519388186,"name":"Woodbranch","pinyin":"woodbranch","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","hatId":"ca_profile_frame_5b7Fd6","hatName":"LV5 头像框","vip":1,"status":2,"fanSize":6,"headSize":6,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":5,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.12","exceedPercentage":"80.26%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":480007350227000,"gmtCreate":1758213262874,"gmtModify":1758213266138,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/01310\">$HKBN(01310)$</a> <a href=\"https://ttm.financial/S/01310\">$HKBN(01310)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/01310\">$HKBN(01310)$</a> <a href=\"https://ttm.financial/S/01310\">$HKBN(01310)$</a>&nbsp;","text":"$HKBN(01310)$ $HKBN(01310)$","images":[{"img":"https://community-static.tradeup.com/news/10ea68997b3c104f682e7c7a32f6e0d5","width":"364","height":"572"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/480007350227000","isVote":1,"tweetType":1,"viewCount":941,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":466858157396280,"gmtCreate":1755016798230,"gmtModify":1755016800616,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$&nbsp;</a><a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$&nbsp;</a><a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$&nbsp;</a>&nbsp;","text":"$Sea Ltd(SE)$ $Sea Ltd(SE)$ $Sea Ltd(SE)$","images":[{"img":"https://community-static.tradeup.com/news/7c822dc2b990873a1580fd1c42ec8221","width":"364","height":"572"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/466858157396280","isVote":1,"tweetType":1,"viewCount":1011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":340162317475968,"gmtCreate":1724051661746,"gmtModify":1724051665710,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SEJ.SI\">$NoonTalk Media(SEJ.SI)$</a> Hitting 0 soon","listText":"<a href=\"https://ttm.financial/S/SEJ.SI\">$NoonTalk Media(SEJ.SI)$</a> Hitting 0 soon","text":"$NoonTalk Media(SEJ.SI)$ Hitting 0 soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/340162317475968","isVote":1,"tweetType":1,"viewCount":2188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":332647088873720,"gmtCreate":1722220519167,"gmtModify":1722220523230,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","listText":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","text":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/332647088873720","repostId":"1162539099","repostType":2,"isVote":1,"tweetType":1,"viewCount":2692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328874739536088,"gmtCreate":1721316901969,"gmtModify":1721316905428,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328874739536088","repostId":"2452177348","repostType":2,"repost":{"id":"2452177348","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1721293372,"share":"https://ttm.financial/m/news/2452177348?lang=en_US&edition=fundamental","pubTime":"2024-07-18 17:02","market":"us","language":"en","title":"BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2452177348","media":"Reuters","summary":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more t","content":"<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-07-18 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4592":"伊斯兰概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","NVO":"诺和诺德","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","BK4532":"文艺复兴科技持仓","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4581":"高盛持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","PFE":"辉瑞","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4534":"瑞士信贷持仓","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2452177348","content_text":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.   Full view will be published shortly.   Follow @aimeedonnellan on X   CONTEXT NEWS   Roche said on July 17 that a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. (Editing by Neil Unmack and Oliver Taslic)((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))","news_type":1,"symbols_score_info":{"NVO":1,"PFE":0.8}},"isVote":1,"tweetType":1,"viewCount":1998,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":271385007149168,"gmtCreate":1707293886836,"gmtModify":1707293891450,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"Anyone has the full article","listText":"Anyone has the full article","text":"Anyone has the full article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/271385007149168","repostId":"2409913541","repostType":2,"isVote":1,"tweetType":1,"viewCount":2921,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9031765144,"gmtCreate":1646672052021,"gmtModify":1676534149273,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","listText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","text":"$Grab Holdings(GRAB)$if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031765144","isVote":1,"tweetType":1,"viewCount":3205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}